Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
David Berd. (2023) Portrait of an autologous cancer vaccine: Then and now. Human Vaccines & Immunotherapeutics 19:1.
Read now
Read now
Ioannis M. Koukourakis & Michael I. Koukourakis. (2023) Combining the past and present to advance immuno-radiotherapy of cancer. International Reviews of Immunology 42:1, pages 26-42.
Read now
Read now
Sabry A. El-Naggar, Ibrahim B. Abdel-Farid, Mousa O. Germoush, Hassan A. Elgebaly & Abeer A. Alm-Eldeen. (2016) Efficacy of Rosmarinus officinalis leaves extract against cyclophosphamide-induced hepatotoxicity. Pharmaceutical Biology 54:10, pages 2007-2016.
Read now
Read now
Leona A Holmberg & Brenda M Sandmaier. (2001) Theratope® vaccine (STn-KLH). Expert Opinion on Biological Therapy 1:5, pages 881-891.
Read now
Read now
Malcolm S. Mitchell. (1991) Attempts to Optimize Active Specific Immunotherapy for Melanoma. International Reviews of Immunology 7:4, pages 331-347.
Read now
Read now
Joseph G. Sinkovics. (1991) Viral Oncolysates as Human Tumor Vaccines. International Reviews of Immunology 7:4, pages 259-287.
Read now
Read now
Articles from other publishers (39)
Mitesh Dwivedi, Sanjay Tiwari, E. Helen Kemp & Rasheedunnisa Begum. (2022) Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics. Heliyon 8:8, pages e10450.
Crossref
Crossref
Abdul Saied, Venu G. Pillarisetty & Steven C. Katz. (2014) Immunotherapy for solid tumors—a review for surgeons. Journal of Surgical Research 187:2, pages 525-535.
Crossref
Crossref
Lana E. Kandalaft, Klara Balint, Jonathan S. Berek & George Coukos. 2014. Controversies in the Management of Gynecological Cancers. Controversies in the Management of Gynecological Cancers
323
337
.
Lana E Kandalaft, Cheryl L Chiang, Janos Tanyi, Greg Motz, Klara Balint, Rosemarie Mick & George Coukos. (2013) A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. Journal of Translational Medicine 11:1, pages 149.
Crossref
Crossref
Antonella Sistigu, Sophie Viaud, Nathalie Chaput, Laura Bracci, Enrico Proietti & Laurence Zitvogel. (2011) Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Seminars in Immunopathology 33:4, pages 369-383.
Crossref
Crossref
Lana E. Kandalaft, Nathan Singh, John B. Liao, Andrea Facciabene, Jonathan S. Berek, Daniel J. PowellJr.Jr. & George Coukos. (2010) The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade. Gynecologic Oncology 116:2, pages 222-233.
Crossref
Crossref
Joris D. Veltman, Margaretha E. H. Lambers, Menno van Nimwegen, Sanne de Jong, Rudi W. Hendriks, Henk C. Hoogsteden, Joachim G. J. V. Aerts & Joost P. J. J. Hegmans. (2010) Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity. Journal of Biomedicine and Biotechnology 2010, pages 1-10.
Crossref
Crossref
Giuseppe Valentino Masucci, Eva Månsson-Brahme, Boel Ragnarsson-Olding, Bo Nilsson, Gunnar Wagenius & Johan Hansson. (2006) Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. Melanoma Research 16:4, pages 357-363.
Crossref
Crossref
Rimas J. Orentas, M. Eric Kohler & Bryon D. Johnson. (2006) Suppression of anti-cancer immunity by regulatory T cells: Back to the future. Seminars in Cancer Biology 16:2, pages 137-149.
Crossref
Crossref
Margalit B. Mokyr, Aaron T. Place, James E. Artwohl & VE Ted Valli. (2005) Importance of signaling via the IFN-α/β receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor. Cancer Immunology, Immunotherapy 55:4, pages 459-468.
Crossref
Crossref
Nuhad K. Ibrahim & James Lee Murray. (2003) Clinical Development of the STn-KLH Vaccine (Theratope®). Clinical Breast Cancer 3, pages S139-S143.
Crossref
Crossref
Kwang-Mi Kim, Ho Won Kim, Jae-Ouk Kim, Kyoung-Min Baek, Joong Gon Kim & Chang-Yuil Kang. (2002) Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes. Immunology 107:4, pages 472-479.
Crossref
Crossref
Vladimir M. Jovasevic & Margalit B. Mokyr. (2001) Melphalan-Induced Expression of IFN-β in MOPC-315 Tumor-Bearing Mice and Its Importance for the Up-Regulation of TNF-α Expression. The Journal of Immunology 167:9, pages 4895-4901.
Crossref
Crossref
Manjula Donepudi, Pradip Raychaudhuri, Jeffrey A. Bluestone & Margalit B. Mokyr. (2001) Mechanism of Melphalan-Induced B7-1 Gene Expression in P815 Tumor Cells. The Journal of Immunology 166:11, pages 6491-6499.
Crossref
Crossref
John Nemunaitis. (1999) Oncolytic Viruses. Investigational New Drugs 17:4, pages 375-386.
Crossref
Crossref
Mark R. Hemmila & Alfred E. Chang. (1999) Clinical implications of the new biology in the development of melanoma vaccines. Journal of Surgical Oncology 70:4, pages 263-274.
Crossref
Crossref
David W. Ollila, Mark C. Kelley, Guy Gammon & Donald L. Morton. (1998) Overview of melanoma vaccines: Active specific immunotherapy for melanoma patients. Seminars in Surgical Oncology 14:4, pages 328-336.
Crossref
Crossref
Arnold M. Conforti, David W. Ollila, Mark C. Kelley, Guy Gammon & Donald L. Morton. (1997) Update on active specific immunotherapy with melanoma vaccines. Journal of Surgical Oncology 66:1, pages 55-64.
Crossref
Crossref
Marie-France Demierre & Howard K. Koh. (1997) Adjuvant therapy for cutaneous malignant melanoma. Journal of the American Academy of Dermatology 36:5, pages 747-764.
Crossref
Crossref
A. Maraveyas & A. G. Dalgleish. 1997. Vaccine Design. Vaccine Design
129
146
.
Stanley P.L. Leong. (1996) IMMUNOTHERAPY OF MALIGNANT MELANOMA. Surgical Clinics of North America 76:6, pages 1355-1381.
Crossref
Crossref
Hulbert K.B. Silver, Richard J. Klasa & Marcel B. Bally. (1996) Genetic allogenization of malignant melanoma. Transfusion Science 17:1, pages 169-174.
Crossref
Crossref
MATTHEW F. MESCHER. (2006) Molecular Interactions in the Activation of Effector and Precursor Cytotoxic T Lymphocytes. Immunological Reviews 146:1, pages 177-210.
Crossref
Crossref
PETER HERSEY. (1993) Evaluation of Vaccinia Viral Lysates as Therapeutic Vaccines in the Treatment of Melanoma. Annals of the New York Academy of Sciences 690:1 Specific Immu, pages 167-177.
Crossref
Crossref
George F. Murphy, Antoaneta Radu, Michael Kaminer & David Berd. (1993) Autologous Melanoma Vaccine Induces Inflammatory Responses in Melanoma Metastases: Relevance to Immunologic Regression and Immunothererapy.. Journal of Investigative Dermatology 100:3, pages 335S-341S.
Crossref
Crossref
George F. Murphy, Antoaneta Radu, Michael Kaminer & David Berd. (1993) Autologous Melanoma Vaccine Induces Inflammatory Responses in Melanoma Metastases: Relevance to Immunologic Regression and Immunotherapy. Journal of Investigative Dermatology 100:3, pages S335-S341.
Crossref
Crossref
Chouhei Sakakura, Toshio Takahashi, Akeo Hagiwara, Tetsuro Yamane, Michitoshi Itoh, Satoshi Shobayashi, Sadayuki Sasaki, Kimihiko Ozaki & Hiroyuki Tsujimoto. (1993) Enhancement of various non-specific immune effector functions in mice by local injection of aclacinomycin A adsorbed onto activated carbon particles (ACR-CH). International Journal of Immunopharmacology 15:2, pages 245-254.
Crossref
Crossref
Larry M. Weiskirch & Margalit B. Mokyr. (2006) Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan‐treated BALB/C mice bearing a large MOPC‐315 tumor. International Journal of Cancer 51:1, pages 84-92.
Crossref
Crossref
Peter Hersey. (1992) Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World Journal of Surgery 16:2, pages 251-260.
Crossref
Crossref
Eli Kedar & Eva Klein. 1992.
245
322
.
Myrtha Basile, Bruce Moskowitz, James Harris, Neil Blumberg & John M. Bennett. (2006) Malignant melanoma: Primary presentation in bone marrow and lymph node. Medical and Pediatric Oncology 20:1, pages 75-77.
Crossref
Crossref
June Kan-Mitchell, Peter E. Liggett, William Harel, Lawrence Steinman, Taizo Nitta, Jorge R. Oksenberg, Marshall R. Posner & Malcolm S. Mitchell. (1991) Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients. Cancer Immunology Immunotherapy 33:5, pages 333-340.
Crossref
Crossref
Masashi Komatsumoto, Masuo Hosokawa, Futoshi Okada, Takeshi Okayasu, Tatsuzo Tanabe & Hiroshi Kobayashi. (1991) The improved effects of specific active immunotherapy on a rat fibrosarcoma by antitumor drugs. Cancer Immunology Immunotherapy 33:5, pages 279-284.
Crossref
Crossref
Mary M. Bartik, Barbara A. Baumgartel-Scofield & Margalit B. Mokyr. (1991) Enhanced expansion of the thymic CD8+ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers. Cancer Immunology Immunotherapy 34:2, pages 79-89.
Crossref
Crossref
Marialuisa Sensi, Marzia Bergomi, Franca Formelli & Giorgio Parmiani. (2006)
Eradication of a disseminated mouse lymphoma by 1,3‐BIS(2‐chloroethyl)‐1‐nitrosourea is immunologically mediated and accompanied by
de novo
generation of anti‐tumor cytotoxicity
. International Journal of Cancer 46:6, pages 1088-1094.
Crossref
Crossref
P. Hersey, H. Werkman & A. E. Edwards. (1990) Western blot analysis of serological responses following immunization with vaccinia viral lysates of melanoma cells. International Journal of Cancer 46:4, pages 612-617.
Crossref
Crossref
Jean-Claude Bystryn. (1990) Tumor vaccines. Cancer and Metastasis Reviews 9:1, pages 81-91.
Crossref
Crossref
M. J. Mastrangelo & D. Berd. 1990. Human Melanoma. Human Melanoma
497
512
.
Sheldon Dray & Margalit B. Mokyr. (1989) Cyclophosphamide and melphalan as immunopotentiating agents in cancer therapy. Medical Oncology and Tumor Pharmacotherapy 6:1, pages 77-85.
Crossref
Crossref